Recommends performing a dexamethasone suppression test to evaluate for autonomous cortisol secretion in patients with primary aldosteronism and adrenal adenoma. Triggered when a clinician considers whether to perform a dexamethasone suppression test in a patient with PA and adrenal adenoma.
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill endo-pa-dexamethasone-suppression-test --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Endo Pa Dexamethasone Suppression Test?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-pa-dexamethasone-suppression-test)More formats (shields.io, HTML) on the badges page.
---
name: endo-pa-dexamethasone-suppression-test
description: Recommends performing a dexamethasone suppression test to evaluate for autonomous cortisol secretion in patients with primary aldosteronism and adrenal adenoma. Triggered when a clinician considers whether to perform a dexamethasone suppression test in a patient with PA and adrenal adenoma.
---
# Perform dexamethasone suppression test in PA patients with adrenal adenoma
## STEP 1 — Gather Information
Confirm PA diagnosis and adrenal adenoma on cross-sectional imaging; review medications for CYP3A4 inducers (e.g., anticonvulsants, rifampin) or agents affecting dexamethasone metabolism; check serum potassium and baseline cortisol if available; ensure patient can comply with overnight fasting and oral dexamethasone administration.
**Action:** If eligible, proceed to administer the dexamethasone suppression test.
## STEP 2 — Rule In / Rule Out
Administer 1 mg dexamethasone orally between 23:00 and 24:00; draw serum cortisol at 08:00–09:00 the next morning.
**Decision:** If serum cortisol >1.8 μg/dL (50 nmol/L), rule in autonomous cortisol secretion (ACS); if ≤1.8 μg/dL, rule out ACS.
## STEP 3 — Classify or Stratify
If ACS is ruled in, order confirmatory tests: 24-hour urinary free cortisol and midnight salivary cortisol; consider plasma metanephrine during adrenal venous sampling if AVS is planned for PA subtyping.
**Action:** Initiate follow-up testing to characterize cortisol excess severity.
## STEP 4 — Decide
If follow-up tests confirm ACS, plan for perioperative stress-dose glucocorticoids due to risk of postoperative adrenal insufficiency; if ACS is ruled out, proceed with PA management per guideline (e.g., mineralocorticoid receptor antagonist or adrenalectomy).
**Decision:** Tailor surgical or medical approach based on cortisol secretion status.
## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on the dexamethasone suppression test for Cushing syndrome diagnosis; false positives may occur with oral estrogen, obesity, major depression, alcohol use, or acute illness. False negatives are rare but possible with dexamethasone malabsorption, CYP3A4 inducers, or incorrect dosing. Do not use test results to direct PA-specific therapy; its role is to evaluate autonomous cortisol secretion only. Avoid testing in patients unable to comply with overnight protocol or with known dexamethasone hypersensitivity.
## Concrete Clinical Example
A 48-year-old man with PA and a 1.1 cm right adrenal adenoma on CT undergoes dexamethasone suppression test; serum cortisol next morning is 2.0 μg/dL (>1.8). Follow-up 24-hour urinary free cortisol is 120 μg/24h (elevated) and midnight salivary cortisol is 1.2 μg/dL (high). He is diagnosed with mild autonomous cortisol secretion. Prior to laparoscopic adrenalectomy, he receives stress-dose hydrocortisone perioperatively.
**Source:** Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, https://doi.org/10.1210/clinem/dgaf284
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!